Optimal Testosterone Control and Eligard®

European Urology, Supplements

Volumn 6, Issue 12, 2007, Pages 754-760

  Tombal, Bertrand ^a   Berges, Richard ^b  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b PAN Klinik am Neumarkt   (Germany)

Author keywords

Eligard; Hormone therapy; Leuprolide; Luteinising hormone releasing hormone agonist; Prostate cancer; Testosterone

Indexed keywords

BUSERELIN; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TRIPTORELIN;

APPETITE; ASTHENIA; CARDIOVASCULAR DISEASE; CASTRATION; CLINICAL TRIAL; CONSTIPATION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; EDEMA; GYNECOMASTIA; HORMONAL THERAPY; HOT FLUSH; HUMAN; LETHARGY; MUSCULOSKELETAL PAIN; NAUSEA; ORCHIECTOMY; PATIENT MONITORING; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SURGICAL TECHNIQUE; TESTIS ATROPHY; TESTOSTERONE BLOOD LEVEL; THORAX PAIN; TREATMENT OUTCOME;

EID: 34248231262     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2007.04.001     Document Type: Review

References (38)

1. http://www.cancer.org/docroot/CRI/content/CRI_2_4_1X_What_are_the_key_statistics_for_prostate_cancer_36.asp?rnav=cri. Accessed at 2007.
2. Huggins C., and Hodges C.V. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatase in metastatic carcinoma of the prostate. Cancer Res 1 (1941) 293-297
3. Huggins C., Stevens R., and Hodges C.V. Studies on prostate cancer. II. The effect of castration on advanced carcinoma of the prostate gland. Arch Surg 43 (1941) 209-223
4. Boccon-Gibod L. Optimising hormone therapy in advanced disease. Eur Urol Suppl 4 8 (2005) 21-29
5. Klotz L. Optimising hormone therapy in localised and early disease. Eur Urol Suppl 4 8 (2005) 12-20
6. Oefelein M.G., and Resnick M.I. Effective testosterone suppression for patients with prostate cancer: is there a best castration?. Urology 62 (2003) 207-213
7. Kaisary A.V., Tyrrell C.J., Peeling W.B., and Griffiths K. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol 67 (1991) 502-508
8. Lin B.J., Chen K.K., Chen M.T., and Chang L.S. The time for serum testosterone to reach castrate level after bilateral orchiectomy or oral estrogen in the management of metastatic prostatic cancer. Urology 43 (1994) 834-837
9. Oefelein M.G., Feng A., Scolieri M.J., Ricchiutti D., and Resnick M.I. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology 56 (2000) 1021-1024
10. Rohl H.F., and Beuke H.P. Effect of orchidectomy on serum concentrations of testosterone and dihydrotestosterone in patients with prostatic cancer. Scand J Urol Nephrol 26 (1992) 11-14
11. Vogelzang N.J., Chodak G.W., Soloway M.S., et al. Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group. Urology 46 (1995) 220-226
12. Zlotta A., and Debruyne F.M.J. Expert opinion on optimal testosterone control in prostate cancer. Eur Urol Suppl 4 8 (2005) 37-41
13. Schally A.V., Kastin A.J., and Arimura A. Hypothalamic follicle-stimulating hormone (FSH) and luteinizing hormone (LH)-regulating hormone: structure, physiology, and clinical studies. Fertil Steril 22 (1971) 703-721
14. Cassileth B.R., Soloway M.S., Vogelzang N.J., et al. Quality of life and psychosocial status in stage D prostate cancer. Zoladex Prostate Cancer Study Group. Qual Life Res 1 (1992) 323-329
15. Potosky A.L., Knopf K., Clegg L.X., et al. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. J Clin Oncol 19 (2001) 3750-3757
16. Morote J., Esquena S., Abascal J.M., et al. Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer. Urol Int 77 (2006) 135-138
17. Oefelein M.G., and Cornum R. Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm. J Urol 164 (2000) 726-729
18. Sarosdy M.F., Schellhammer P.F., Soloway M.S., et al. Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer. BJU Int 83 (1999) 801-806
19. Kawakami J., and Morales A. A comprehensive hormonal evaluation in patients with cancer of the prostate on androgen suppression with LHRH agonists. J Urol 167 Suppl (2002) 288 (abstract no. 1135)
20. McLeod D., Zinner N., Tomera K., et al. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology 58 (2001) 756-761
21. Sharifi R., and Browneller R. Serum testosterone suppression and potential for agonistic stimulation during chronic treatment with monthly and 3-month depot formulations of leuprolide acetate for advanced prostate cancer. J Urol 168 (2002) 1001-1004
22. Fontana D., Mari M., Martinelli A., et al. 3-month formulation of goserelin acetate ('Zoladex' 10.8-mg depot) in advanced prostate cancer: results from an Italian, open, multicenter trial. Urol Int 70 (2003) 316-320
23. Jocham D. Leuprorelin three-month depot in the treatment of advanced and metastatic prostate cancer: long-term follow-up results. Urol Int 60 Suppl 2 (1998) 18-24
24. Khan M.S., and O'Brien A. An evaluation of pharmacokinetics and pharmacodynamics of leuprorelin acetate 3M-depot in patients with advanced and metastatic carcinoma of the prostate. Urol Int 60 (1998) 33-40
25. Popov I., Jelic S., Radosavljevic D., and Nikolic-Tomasevic Z. Androgen level variations, clinical response to LHRH agonists and changes in the quality of life subscales in metastatic prostate cancer--speculations about possible role of the monoamine system. Neoplasma 44 (1997) 308-313
26. Tombal B. Appropriate castration with luteinising hormone releasing hormone (LHRH) agonists: what is the optimal level of testosterone?. Eur Urol Suppl 4 5 (2005) 14-19
27. Cox M.C., Scripture C.D., and Figg W.D. Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?. Expert Rev Anticancer Ther 5 (2005) 605-611
28. Ravivarapu H.B., Moyer K.L., and Dunn R.L. Sustained activity and release of leuprolide acetate from an in situ forming polymeric implant. AAPS PharmSciTech 1 (2000) E1
29. Perez-Marrero R., and Tyler R.C. A subcutaneous delivery system for the extended release of leuprolide acetate for the treatment of prostate cancer. Expert Opin Pharmacother 5 (2004) 447-457
30. Chu F.M., Jayson M., Dineen M.K., Perez R., Harkaway R., and Tyler R.C. A clinical study of 22.5 mg. LA-2550: a new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 168 (2002) 1199-1203
31. Crawford E.D., Sartor O., Chu F., Perez R., Karlin G., and Garrett J.S. A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 175 (2006) 533-536
32. Perez-Marreno R., Chu F.M., Gleason D., Loizides E., Wachs B., and Tyler R.C. A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer. Clin Ther 24 (2002) 1902-1914
33. ® 6: A new form of treatment for prostate cancer. Eur Urol Suppl 5 (2006) 905-910
34. ® leuprolide implant in patients with prostate cancer: efficacy and safety results from two long-term phase I/II and II studies. The Viadur Study Group. J Urol 163 Suppl 4 (2000) 262-263
35. Rizzo M., Mazzei T., Mini E., Bartoletti R., and Periti P. Leuprorelin acetate depot in advanced prostatic cancer: a phase II multicentre trial. J Int Med Res 18 Suppl 1 (1990) 114-125
36. Sharifi R., Bruskewitz R.C., Gittleman M.C., Graham S.D., Hudson P.B., and Stein B. Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer. Clin Ther 18 (1996) 647-657
37. Wechsel H.W., Zerbib M., Pagano F., and Coptcoat M.J. Randomized open labelled comparative study of the efficacy, safety and tolerability of leuprorelin acetate 1M and 3M depot in patients with advanced prostatic cancer. Eur Urol 30 Suppl 1 (1996) 7-14
38. Fowler J.E., Gottesman J.E., Reid C.F., Andriole G.L., and Soloway M.S. Safety and efficacy of an implantable leuprolide delivery system in patients with advanced prostate cancer. J Urol 164 (2000) 730-734